Indication
Acute promyelocytic leukemia
Acute promyelocytic leukemia is an aggressive subtype of acute myeloid leukemia characterized by an abnormal accumulation of immature granulocyte precursors, known as promyelocytes, within the bone marrow and peripheral blood. Read more about Acute promyelocytic leukemia
50 drugs 38 manufacturers
Drugs that treat it
Common Acute promyelocytic leukemia therapies.
ARSENIC TRIOXIDE
ARSENIC TRIOXIDE
ARSENIC TRIOXIDE
ARSENIC TRIOXIDE
ARSENIC TRIOXIDE
DAUNORUBICIN HCL
TRETINOIN
ARSENIC TRIOXIDE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAcute promyelocytic leukemia is an aggressive subtype of acute myeloid leukemia characterized by an abnormal accumulation of immature granulocyte precursors, known as promyelocytes, within the bone marrow and peripheral blood.
Affecting both adults and children, it is primarily driven by a balanced reciprocal translocation between chromosomes 15 and 17, creating the pathognomonic PML-RARA fusion oncogene that arrests normal myeloid cell differentiation.
Patients typically present with manifestations of cytopenias—such as fatigue, infection, and marked pallor—alongside a severe, life-threatening coagulopathy marked by disseminated intravascular coagulation, hyperfibrinolysis, and catastrophic bleeding risks.
- cancer.gov
Acute promyelocytic leukemia is an aggressive subtype of acute myeloid leukemia characterized by an abnormal accumulation of immature granulocyte precursors, known as promyelocytes, within the bone marrow and peripheral blood
- nih.gov
Acute promyelocytic leukemia is an aggressive subtype of acute myeloid leukemia characterized by an abnormal accumulation of immature granulocyte precursors, known as promyelocytes, within the bone marrow and peripheral blood Patients typically present with manifestations of cytopenias—such as fatigue, infection, and marked pallor—alongside a severe, life-threatening coagulopathy marked by disseminated intravascular coagulation, hyperfibrinolysis, and catastrophic bleeding risks
- nih.gov
Affecting both adults and children, it is primarily driven by a balanced reciprocal translocation between chromosomes 15 and 17, creating the pathognomonic PML-RARA fusion oncogene that arrests normal myeloid cell differentiation
- cancer.gov
Affecting both adults and children, it is primarily driven by a balanced reciprocal translocation between chromosomes 15 and 17, creating the pathognomonic PML-RARA fusion oncogene that arrests normal myeloid cell differentiation Patients typically present with manifestations of cytopenias—such as fatigue, infection, and marked pallor—alongside a severe, life-threatening coagulopathy marked by disseminated intravascular coagulation, hyperfibrinolysis, and catastrophic bleeding risks
- nih.gov
Affecting both adults and children, it is primarily driven by a balanced reciprocal translocation between chromosomes 15 and 17, creating the pathognomonic PML-RARA fusion oncogene that arrests normal myeloid cell differentiation
- nih.gov
Patients typically present with manifestations of cytopenias—such as fatigue, infection, and marked pallor—alongside a severe, life-threatening coagulopathy marked by disseminated intravascular coagulation, hyperfibrinolysis, and catastrophic bleeding risks
Personalize your experience
Follow Acute promyelocytic leukemia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.